產(chǎn)品名稱：Lapatinib Ditosylate 產(chǎn)品貨號：LKT L0360 產(chǎn)品規(guī)格：10 mg Description A treatment FDA approved for breast cancer. It is used in patients whose cancer is HER2 positive. Used for treatment of solid tumors and is an ATP competitive epidermal growth factor and HER2 dual tyrosine kinase inhibitor. More information about Protein Kinase Inhibitors Specifications Cas No. 388082-78-8 Product ID L0360 Product Name Lapatinib Ditosylate Formula Wt. 925.46 Melting Point 236-259oC Solubility Slightly in DMSO Store Temp Ambient References Feng, Yu-fei. Zhongguo Xinyao Zazhi (2007), 16(23), 1990-1993. Nelson, M. H. Therapeutics and Clinical Risk Management (2007), 3(4), 665-673.
滬公網(wǎng)安備 31011002002623號
